Drug Trial Radar · NCT07944690
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX49 in Advanced/Metastatic Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
222
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Dec 2029
Study completion Dec 2030
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Nov 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of HLX49 in patients with advanced/metastatic solid tumors.
Conditions
- Advanced/Metastatic Solid Tumors
Interventions
HLX49Drug
Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
Trastuzumab Deruxtecan for Injection (T-DXd)Drug
Patients with good tolerability and well controlled disease will receive Trastuzumab deruxtecan via intravenous infusion once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Dose-Limiting Toxicity (DLT) of HLX49 within 21 days after the first AdministrationTime frame: From first dose to the end of Cycle 1 (each cycle is 3 weeks).
- The maximum tolerated dose (MTD) of HLX49Time frame: From first dose to the end of Cycle 1 (each cycle is 3 weeks).
- RP2DTime frame: Approximately up to 24 months.
- Objective response rate (ORR) assessed by IRRCTime frame: Approximately up to 24 months.
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Sunshine Coast University Hospital
Sunshine Coast, Australia
Beijing Cancer Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.